Literature DB >> 9048978

Cerebrospinal fluid lactate and glutamine are reduced in multiple sclerosis.

J Aasly1, M Gårseth, U Sonnewald, J A Zwart, L R White, G Unsgård.   

Abstract

OBJECTIVES: To analyse various metabolites in human cerebrospinal fluid from healthy controls and patients with multiple sclerosis. PATIENTS AND METHODS: Cerebrospinal fluid was obtained from patients by lumbar puncture, frozen, redissolved, and analysed for metabolites by proton nuclear magnetic resonance spectroscopy.
RESULTS: Significantly lower values for lactate and glutamine were found in patients with multiple sclerosis in comparison with controls. No significant differences were found between patients with the relapsing-remitting and chronic progressive forms of the disease for any of the metabolites measured.
CONCLUSION: There is a concomitant reduction in both lactate and glutamine in the cerebrospinal fluid of patients with multiple sclerosis compared to controls. This may be related to altered astrocytic metabolism during the disease. The results clearly show the diagnostic potential of magnetic resonance spectroscopy in diseases such as multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9048978     DOI: 10.1111/j.1600-0404.1997.tb00060.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  16 in total

Review 1.  Autoimmune modulation of astrocyte-mediated homeostasis.

Authors:  Thomas Korn; Mahendra Rao; Tim Magnus
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

Review 2.  The role of glial-neuronal metabolic cooperation in modulating progression of multiple sclerosis and neuropathic pain.

Authors:  Rachel R Robinson; Alina K Dietz; Asif M Maroof; Reto Asmis; Thomas G Forsthuber
Journal:  Immunotherapy       Date:  2019-02       Impact factor: 4.196

3.  Axonal damage in multiple sclerosis.

Authors:  Jeffery D Haines; Matilde Inglese; Patrizia Casaccia
Journal:  Mt Sinai J Med       Date:  2011 Mar-Apr

4.  High-resolution nuclear magnetic resonance spectroscopic study of metabolites in the cerebrospinal fluid of patients with cervical myelopathy and lumbar radiculopathy.

Authors:  Hideki Nagashima; Yasuo Morio; Shunsuke Meshitsuka; Koji Yamane; Yoshiro Nanjo; Ryota Teshima
Journal:  Eur Spine J       Date:  2010-05-20       Impact factor: 3.134

Review 5.  The potential roles of amino acids and their major derivatives in the management of multiple sclerosis.

Authors:  Somayeh Pashaei; Reza Yarani; Pantea Mohammadi; Mohammad Sajad Emami Aleagha
Journal:  Amino Acids       Date:  2022-04-26       Impact factor: 3.520

6.  Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression.

Authors:  William T Regenold; Pornima Phatak; Michael J Makley; Roger D Stone; Mitchel A Kling
Journal:  J Neurol Sci       Date:  2008-09-09       Impact factor: 3.181

7.  Age-Related 1H NMR Characterization of Cerebrospinal Fluid in Newborn and Young Healthy Piglets.

Authors:  Domenico Ventrella; Luca Laghi; Francesca Barone; Alberto Elmi; Noemi Romagnoli; Maria Laura Bacci
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

8.  Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid.

Authors:  Norbert W Lutz; Angèle Viola; Irina Malikova; Sylviane Confort-Gouny; Bertrand Audoin; Jean-Philippe Ranjeva; Jean Pelletier; Patrick J Cozzone
Journal:  PLoS One       Date:  2007-07-04       Impact factor: 3.240

9.  (1)H-NMR analysis provides a metabolomic profile of patients with multiple sclerosis.

Authors:  Eleonora Cocco; Federica Murgia; Lorena Lorefice; Luigi Barberini; Simone Poddighe; Jessica Frau; Giuseppe Fenu; Giancarlo Coghe; Maria Rita Murru; Raffaele Murru; Francesco Del Carratore; Luigi Atzori; Maria Giovanna Marrosu
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-12-24

10.  The 1H NMR profile of healthy dog cerebrospinal fluid.

Authors:  Mihai Musteata; Alina Nicolescu; Gheorghe Solcan; Calin Deleanu
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.